(Sioux Falls, SD) – The popular Indian spice curcumin can suppress prostate cancer cell progression, according to a study led by Sanford Research’s Meena Jaggi, PhD, recently published in PLOSONE and featured by UroToday.
“Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1” is available in a full-text version here.
Dr. Jaggi’s research looked at the effect on nuclear B-catenin signaling using curcumin, the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family. Dr. Jaggi’s team of four researchers discovered curcumin can maintain the proper level of protein kinase D1 (PKD1) in prostate cancer cells in a mice model. That level is typically low in subjects experiencing prostate cancer.
“We have demonstrated that curcumin activates PKD1, resulting in more favorable levels and thus putting subjects at a lower risk for prostate cancer,” said Dr. Jaggi. “Modulation of these cellular events by curcumin correlated with decreased cell proliferation, colony formation and cell motility and enhanced cell-cell aggregation in prostate cancer cells.”
The National Cancer Institute reports prostate cancer is the most commonly diagnosed cancer, affecting 1 in 6 males in the United States. Understanding the molecular basis of prostate cancer progression allows for early diagnosis and the development of treatment strategies, such as curcumin, for the disease.
UroToday publishes a full spectrum of online medical articles about urology diseases, including prostate cancer.
About Sanford Research/USD
Sanford Research/USD is a non-profit research organization formed between Sanford Health and the University of South Dakota. Sanford Health is an integrated health system headquartered in Fargo, ND and Sioux Falls, SD and represents the largest, rural, not-for-profit healthcare system in the nation with a presence in 111 communities, eight states and three countries. In 2007, a transformational gift of $400 million by Denny Sanford provided for an expansion of children’s and research initiatives, specifically finding a cure for type 1 diabetes, and has given Sanford Research significant momentum in its goal of becoming one of the premiere research institutions in the United States and the world. Most recently, a subsequent gift of $100 million by Mr. Sanford has paved the way to establish Edith Sanford Breast Cancer Research.
With a team of more than 200 researchers, Sanford Research comprises several research centers, including Children’s Health Research, Edith Sanford Breast Cancer, Cancer Biology, Cardiovascular Health, Center for Health Outcomes and Prevention, and the National Institute for Athletic Health and Performance (NIAHP).